Detalhe da pesquisa
1.
Card9/neutrophil signalling axis promotes IL-17A-mediated ankylosing spondylitis.
Ann Rheum Dis
; 83(2): 214-222, 2024 Jan 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37813481
2.
Bimekizumab treatment in patients with active axial spondyloarthritis: 52-week efficacy and safety from the randomised parallel phase 3 BE MOBILE 1 and BE MOBILE 2 studies.
Ann Rheum Dis
; 83(2): 199-213, 2024 Jan 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37793792
3.
Efficacy and Safety of Tofacitinib in Ankylosing Spondylitis by Baseline C-Reactive Protein Level: Post Hoc Analysis of Phase 2/3 Clinical Trials.
J Rheumatol
; 2024 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38825359
4.
Twenty Years of SPARTAN: From Inception to Impact (SPARTAN 2023 Annual Meeting Proceedings).
Curr Rheumatol Rep
; 26(3): 96-101, 2024 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38214805
5.
Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet
; 400(10349): 369-379, 2022 07 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-35908570
6.
Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials.
Ann Rheum Dis
; 82(4): 515-526, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36649967
7.
Comparative efficacy and safety of bimekizumab in axial spondyloarthritis: a systematic literature review and network meta-analysis.
Rheumatology (Oxford)
; 2023 Nov 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37947318
8.
Safety of ixekizumab in patients with psoriatic arthritis: data from four clinical trials with over 2000 patient-years of exposure.
Ann Rheum Dis
; 81(7): 944-950, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35393269
9.
Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial.
Ann Rheum Dis
; 81(11): 1515-1523, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35788492
10.
Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis.
Ann Rheum Dis
; 81(6): 815-822, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35241426
11.
Ixekizumab in radiographic axial spondyloarthritis with and without elevated C-reactive protein or positive magnetic resonance imaging.
Rheumatology (Oxford)
; 61(11): 4324-4334, 2022 11 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35188180
12.
A review of JAK-STAT signalling in the pathogenesis of spondyloarthritis and the role of JAK inhibition.
Rheumatology (Oxford)
; 61(5): 1783-1794, 2022 05 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-34668515
13.
Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data.
Acta Derm Venereol
; 102: adv00698, 2022 Apr 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-35146532
14.
Differentiating nonradiographic axial spondyloarthritis from its mimics: a narrative review.
BMC Musculoskelet Disord
; 23(1): 240, 2022 Mar 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-35279103
15.
The Safety and Immunologic Effectiveness of the Live Varicella-Zoster Vaccine in Patients Receiving Tumor Necrosis Factor Inhibitor Therapy : A Randomized Controlled Trial.
Ann Intern Med
; 174(11): 1510-1518, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34570596
16.
Axial Spondyloarthritis in the Chiropractic Care Setting: A Systematic Literature Review.
J Clin Rheumatol
; 28(2): e589-e595, 2022 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34294660
17.
Efficacy and Safety of Intravenous Golimumab in Ankylosing Spondylitis Patients With Early and Late Disease Through One Year of the GO-ALIVE Study.
J Clin Rheumatol
; 28(5): 270-277, 2022 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35653615
18.
Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial.
Lancet
; 395(10230): 1115-1125, 2020 04 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32178765
19.
Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial.
Lancet
; 395(10217): 53-64, 2020 01 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31813637
20.
Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study.
Ann Rheum Dis
; 80(8): 1004-1013, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33906853